Table 1.
Clinical and pathological characteristics of patients
| Total n (%) | Distant relapse n (%) | Local relapse n (%) | Died of disease n (%) | DDFS
|
LRFS
|
OS
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | |||||
| Age, years | |||||||||||||
| <50 | 56 (63.64) | 12 (66.67) | 11 (64.71) | 2 (28.57) | 0.99 | 1.01 | 0.37–2.72 | 0.81 | 1.14 | 0.41–3.13 | 0.07 | 4.5 | 0.87–23.16 |
| ≥50 | 32 (36.36) | 6 (33.33) | 6 (35.29) | 5 (71.43) | |||||||||
| ER status | |||||||||||||
| + | 54 (61.36) | 11 (61.11) | 10 (58.82) | 4 (57.14) | 0.89 | 1.07 | 0.40–2.92 | 0.94 | 0.96 | 0.35–2.66 | 0.5 | 0.59 | 0.13–2.72 |
| − | 34 (38.64) | 7 (38.89) | 7 (41.18) | 3 (42.86) | |||||||||
| HER2 status | |||||||||||||
| + | 22 (25.00) | 6 (33.33) | 5 (29.41) | 3 (42.86) | 0.23 | 1.86 | 0.67–5.17 | 0.43 | 1.55 | 0.52–4.65 | 0.36 | 2.04 | 0.45–9.33 |
| − | 66 (75.00) | 12 (66.67) | 12 (70.59) | 4 (57.14) | |||||||||
| Size of IC pre-NACT | |||||||||||||
| T1 | 4 (4.55) | 1 (5.56) | 1 (5.88) | 0 (0.00) | 0.27 | 1.56 | 0.71–3.45 | 0.18 | 1.73 | 0.77–3.88 | 0.03 | 2.96 | 1.11–7.9 |
| T2 | 58 (65.91) | 10 (55.56) | 9 (52.94) | 3 (42.86) | |||||||||
| T3 | 24 (27.27) | 6 (33.33) | 6 (35.29) | 3 (42.86) | |||||||||
| T4 | 2 (2.27) | 1 (5.56) | 1 (5.88) | 1 (14.29) | |||||||||
| Size of IC post-NACT | |||||||||||||
| T0 | 7 (7.95) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0.06 | 1.85 | 0.97–3.54 | 0.05 | 1.94 | 1.00–3.77 | 0.03 | 2.87 | 1.11–7.42 |
| T1 | 50 (56.82) | 9 (50.00) | 8 (47.06) | 2 (28.57) | |||||||||
| T2 | 27 (30.68) | 8 (44.44) | 8 (47.06) | 4 (57.14) | |||||||||
| T3 | 4 (4.55) | 1 (5.56) | 1 (5.88) | 1 (14.29) | |||||||||
| Lymph nodes pre-NACT | |||||||||||||
| N0 | 13 (14.77) | 1 (5.56) | 1 (5.88) | 0 (0.00) | 0.04 | 1.91 | 1.04–3.48 | 0.03 | 2.04 | 1.09–3.81 | 0.41 | 1.53 | 0.56–4.2 |
| N1 | 33 (37.50) | 5 (27.78) | 4 (23.53) | 3 (42.86) | |||||||||
| N2 | 37 (42.05) | 11 (61.11) | 11 (64.71) | 4 (57.14) | |||||||||
| N3 | 5 (5.68) | 1 (5.56) | 1 (5.88) | 0 (0.00) | |||||||||
| Lymph nodes post-NACT | |||||||||||||
| pN0 | 29 (32.95) | 3 (16.67) | 3 (17.65) | 1 (14.29) | 0.06 | 1.54 | 0.99–2.42 | 0.03 | 1.67 | 1.04–2.68 | 0.50 | 1.26 | 0.64–2.5 |
| pN1 | 26 (29.55) | 7 (38.89) | 5 (29.41) | 3 (42.86) | |||||||||
| pN2 | 20 (22.73) | 3 (16.67) | 4 (23.53) | 1 (14.29) | |||||||||
| pN3 | 13 (14.77) | 5 (27.78) | 5 (29.41) | 2 (28.57) | |||||||||
| Ki-67 of IC pre-NACT | |||||||||||||
| + | 61 (69.32) | 11 (61.11) | 10 (58.82) | 4 (57.14) | 0.43 | 0.68 | 0.26–1.8 | 0.39 | 0.64 | 0.24–1.74 | 0.54 | 0.63 | 0.14–2.8 |
| − | 27 (30.68) | 7 (38.89) | 7 (41.18) | 3 (42.86) | |||||||||
| Ki-67 of IC post-NACT | |||||||||||||
| + | 31 (35.23) | 6 (33.33) | 6 (35.29) | 2 (28.57) | 0.87 | 1.09 | 0.40–2.99 | 0.84 | 1.11 | 0.40–3.11 | 0.57 | 0.62 | 0.12–3.25 |
| − | 57 (64.77) | 12 (66.67) | 11 (64.71) | 5 (71.43) | |||||||||
Abbreviations: CI, confidence interval; DDFS, distant disease-free survival; ER, estrogen receptor; HR, hazard ratio; IC, invasive carcinoma; LRFS, locoregional relapse-free survival; NACT, neoadjuvant chemotherapy; OS, overall survival; HER2, human epidermal growth factor receptor 2.